382 related articles for article (PubMed ID: 31429786)
1. Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon.
Patwardhan A; Spencer CH
Pediatr Rheumatol Online J; 2019 Aug; 17(1):56. PubMed ID: 31429786
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy in the idiopathic inflammatory myopathies.
Khoo T; Limaye V
Rheumatol Int; 2020 Feb; 40(2):191-205. PubMed ID: 31680207
[TBL] [Abstract][Full Text] [Related]
3. Biologics in refractory idiopathic inflammatory myositis (IIM): What experience in juvenile vs adult myositis tells us about the use of biologics in pediatric IIM.
Patwardhan A; Spencer CH
Mod Rheumatol; 2021 Sep; 31(5):933-948. PubMed ID: 33499694
[TBL] [Abstract][Full Text] [Related]
4. Local expression of cytokines in idiopathic inflammatory myopathies.
Lepidi H; Frances V; Figarella-Branger D; Bartoli C; Machado-Baeta A; Pellissier JF
Neuropathol Appl Neurobiol; 1998 Feb; 24(1):73-9. PubMed ID: 9549732
[TBL] [Abstract][Full Text] [Related]
5. Dermatomyositis and polymyositis: new treatment targets on the horizon.
Hak AE; de Paepe B; de Bleecker JL; Tak PP; de Visser M
Neth J Med; 2011 Oct; 69(10):410-21. PubMed ID: 22058260
[TBL] [Abstract][Full Text] [Related]
6. Biologics for idiopathic inflammatory myopathies.
Moghadam-Kia S; Aggarwal R; Oddis CV
Curr Opin Rheumatol; 2017 Nov; 29(6):645-651. PubMed ID: 28817464
[TBL] [Abstract][Full Text] [Related]
7. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.
Rider LG; Katz JD; Jones OY
Rheum Dis Clin North Am; 2013 Nov; 39(4):877-904. PubMed ID: 24182859
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy.
Dourmishev LA
Folia Med (Plovdiv); 2017 Mar; 59(1):7-13. PubMed ID: 28384112
[TBL] [Abstract][Full Text] [Related]
9. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
10. [Idiopathic inflammatory myopathies. A review].
Acosta I; Matamala JM; Jara P; Pino F; Gallardo A; Verdugo R
Rev Med Chil; 2019 Mar; 147(3):342-355. PubMed ID: 31344172
[TBL] [Abstract][Full Text] [Related]
11. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.
Moghadam-Kia S; Oddis CV; Aggarwal R
Clin Rev Allergy Immunol; 2017 Feb; 52(1):81-87. PubMed ID: 26767526
[TBL] [Abstract][Full Text] [Related]
12. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.
Lundberg I; Ulfgren AK; Nyberg P; Andersson U; Klareskog L
Arthritis Rheum; 1997 May; 40(5):865-74. PubMed ID: 9153548
[TBL] [Abstract][Full Text] [Related]
13. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies.
Lundberg IE
Curr Rheumatol Rep; 2000 Jun; 2(3):216-24. PubMed ID: 11123062
[TBL] [Abstract][Full Text] [Related]
14. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
Lazarou IN; Guerne PA
J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
[TBL] [Abstract][Full Text] [Related]
15. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies.
Wilkinson MGL; Radziszewska A; Wincup C; Ioannou Y; Isenberg DA; Manson JJ; Jury EC
Rheumatology (Oxford); 2020 Jan; 59(1):194-204. PubMed ID: 31292651
[TBL] [Abstract][Full Text] [Related]
16. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
Wu JQ; Lu MP; Reed AM
World J Pediatr; 2020 Feb; 16(1):31-43. PubMed ID: 31556011
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations.
Ernste FC; Reed AM
Mayo Clin Proc; 2013 Jan; 88(1):83-105. PubMed ID: 23274022
[TBL] [Abstract][Full Text] [Related]
19. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies.
Cappelletti C; Baggi F; Zolezzi F; Biancolini D; Beretta O; Severa M; Coccia EM; Confalonieri P; Morandi L; Mora M; Mantegazza R; Bernasconi P
Neurology; 2011 Jun; 76(24):2079-88. PubMed ID: 21670437
[TBL] [Abstract][Full Text] [Related]
20. Recent clinical trials in idiopathic inflammatory myopathies.
Leclair V; Lundberg IE
Curr Opin Rheumatol; 2017 Nov; 29(6):652-659. PubMed ID: 28763333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
